Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on October 28, 2008
JNCI Journal of the National Cancer Institute 2008 100(21):1487-1488; doi:10.1093/jnci/djn368
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/21/1487    most recent
djn368v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Thompson, I. M.
Right arrow Articles by Kristal, A. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thompson, I. M.
Right arrow Articles by Kristal, A. R.
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press.

EDITORIALS

Prostate-Specific Antigen: A Misused and Maligned Prostate Cancer Biomarker

Ian M. Thompson, Catherine M. Tangen, Alan R. Kristal

Affiliations of authors: Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX; Fred Hutchinson Cancer Research Center, Seattle, Washington, DC

Correspondence to: Ian M. Thompson, MD, Department of Urology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78229 (e-mail: thompsoni@uthscsa.edu).

The first 10% of the full text of this article appears below.

Prostate cancer is a conundrum. It is ubiquitous in aging men and, although the lifetime risk of death is only about 3%, it causes almost 30 000 deaths per year. The cancer is asymptomatic until metastatic and at that stage, median survival is about 3 years. The advent of prostate-specific antigen (PSA) testing in combination with ultrasound-guided biopsy has dramatically increased cancer detection; a PSA test result is currently the "prompt" for the majority of prostate biopsies, and although only about half of the population receives regular PSA testing, it has effectively doubled the lifetime risk of receiving a prostate cancer diagnosis. It is currently unclear to what extent PSA screening has decreased . . . [Full Text of this Article]

Funding


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

In This Issue
J Natl Cancer Inst 2008 100: 1485. [Extract] [Full Text] [PDF]

Statin Use Associated with Reduction in Prostate Specific Antigen Levels
J Natl Cancer Inst 2008 100: 1486. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
R. J. Hamilton, E. A. Platz, and S. J. Freedland
Re: Prostate-Specific Antigen: A Misused and Maligned Prostate Cancer Biomarker
J Natl Cancer Inst, April 15, 2009; 101(8): 611 - 612.
[Full Text] [PDF]

Home page
 JWatch Oncology and HematologyHome page
Statins and Prostate-Specific Antigen Levels
Journal Watch Oncology and Hematology, November 25, 2008; 2008(1125): 1 - 1.
[Full Text]